Non-alcoholic fatty liver disease surgery: Difference between revisions

Jump to navigation Jump to search
 
(12 intermediate revisions by 2 users not shown)
Line 4: Line 4:
   
   
==Overview==
==Overview==
Surgery is not the first-line treatment option for patients with NAFLD.The mainstay of treatment for NAFLD is medical therapy and [[weight loss]].
Surgery is not the first-line treatment option for patients with non- Alcoholic fatty liver disease (NAFLD). However, [[gastric bypass surgery]] is recommended in patients with non-alcoholic fatty liver disease whose [[Body mass index|BMI]] is greater than 40 who psychologically stable and failed medical therapy.


==Surgery==
== Surgery ==
* Given the importance of weight loss, the outcomes of [[Bariatrics|bariatric]] surgical procedure at the natural records of NAFLD were pronounced with the aid of numerous groups.<ref name="pmid2591798">{{cite journal |vauthors=Sukhanova NN |title=[Somatotypes in evaluating the physical development of 11-year-old schoolchildren] |language=Russian |journal=Gig Sanit |volume= |issue=9 |pages=84–6 |year=1989 |pmid=2591798 |doi= |url=}}</ref>
 
* Meta-analyses show that diverse bariatric surgical modalities yielding loss of 20% to 40% of baseline [[Body mass index|BMI]] bring about substantial histologic development. 
==== Indications ====
* Few sufferers enjoy entire resolution of NASH.
* Patients with NAFLD and [[BMI]] greater than 40 who psychologically stable
* [[Bariatric surgery]] is associated with a massive improvement in each histological and biochemical markers of NAFLD.<ref name="pmid28507929">{{cite journal |vauthors=Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J |title=Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies |journal=J Clin Transl Hepatol |volume=5 |issue=1 |pages=67–75 |year=2017 |pmid=28507929 |pmc=5411359 |doi=10.14218/JCTH.2016.00061 |url=}}</ref>
* In patients who failed medical therapy.
* Further studies is needed to understand the precise mechanisms and future studies have to focus on better tiers of proof to higher pick out the advantages of bariatric surgical operation on liver disease so one can enhance destiny treatment strategies within the management of NAFLD.
 
==== Surgical options ====
* The most common procedures are [[Adjustable gastric banding surgery|adjustable gastric banding]] and the [[Roux-en-Y|Roux-en-Y bypass]].<ref name="pmid28507929">{{cite journal |vauthors=Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J |title=Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies |journal=J Clin Transl Hepatol |volume=5 |issue=1 |pages=67–75 |year=2017 |pmid=28507929 |pmc=5411359 |doi=10.14218/JCTH.2016.00061 |url=}}</ref>
* A Y-shaped section of the [[ileum|i  bum]] is attached to the pouch so that [[food]] bypasses the [[duodenum]] and [[Jejunum|proximal section of the jejunum]].
* A laparoscopic sleeve gastrectomy may be a secure and powerful treatment of weight problems in adult patients. Significant and sustained weight reduction results in the improvement NAFLD.<ref name="pmid29264490">{{cite journal |vauthors=Boscolo M, Féry F, Cnop M |title=Beneficial Outcomes of Sleeve Gastrectomy in a Morbidly Obese Patient With Bardet-Biedl Syndrome |journal=J Endocr Soc |volume=1 |issue=4 |pages=317–322 |year=2017 |pmid=29264490 |doi=10.1210/js.2017-00071 |url=}}</ref><ref name="pmid25105982">{{cite journal |vauthors=Colquitt JL, Pickett K, Loveman E, Frampton GK |title=Surgery for weight loss in adults |journal=Cochrane Database Syst Rev |volume= |issue=8 |pages=CD003641 |year=2014 |pmid=25105982 |doi=10.1002/14651858.CD003641.pub4 |url=}}</ref>
 
* The size of the [[stomach]] is reduced either by stapling or [[Banding (medical)|banding]], creating a small pouch, assisting with [[weight loss]] by inducing
** Earlier [[satiety]]
** [[Calorie restriction|Reducing caloric intake]]
** Decreasing absorptive capacity
* The feasibility of liver transplantation depends on the stage of NAFLD at diagnosis.NAFLD is emerging as the second most common cause for liver transplant.<ref name="pmid29249127">{{cite journal |vauthors=Germani G, Becchetti C |title=Liver transplantation for non-alcoholic fatty liver disease |journal=Minerva Gastroenterol Dietol |volume= |issue= |pages= |year=2017 |pmid=29249127 |doi=10.23736/S1121-421X.17.02467-9 |url=}}</ref><ref name="pmid28744836">{{cite journal |vauthors=Cholankeril G, Wong RJ, Hu M, Perumpail RB, Yoo ER, Puri P, Younossi ZM, Harrison SA, Ahmed A |title=Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes |journal=Dig. Dis. Sci. |volume=62 |issue=10 |pages=2915–2922 |year=2017 |pmid=28744836 |doi=10.1007/s10620-017-4684-x |url=}}</ref>
** '''Indication 1''' End stage liver-disease  
** '''Indication 2''' Hepatocellular carcinoma (HCC) are the two most important indications for the liver transplant.
** '''Outcome :''' After liver transplanation patients with or without NASH may survive 1,3 and 5 years and are increasinly at risk for cardio vascular risks.<ref name="pmid24076414">{{cite journal |vauthors=Wang X, Li J, Riaz DR, Shi G, Liu C, Dai Y |title=Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis |journal=Clin. Gastroenterol. Hepatol. |volume=12 |issue=3 |pages=394–402.e1 |year=2014 |pmid=24076414 |doi=10.1016/j.cgh.2013.09.023 |url=}}</ref>
 
==== Complications ====
* Early complications include:
** [[Peritonitis]]
** [[Pulmonary embolism]]
* Late complications include
** [[Nutritional deficiencies]]
** [[Iron deficiency anemia]]
** [[Dumping syndrome]]
** [[Ulcers]]


==References==
==References==

Latest revision as of 16:32, 27 December 2017

Non-Alcoholic Fatty Liver Disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Non-Alcoholic Fatty Liver Disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case studies

Case #1

Non-alcoholic fatty liver disease surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Non-alcoholic fatty liver disease surgery

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Non-alcoholic fatty liver disease surgery

CDC on Non-alcoholic fatty liver disease surgery

Non-alcoholic fatty liver disease surgery in the news

Blogs on Non-alcoholic fatty liver disease surgery

Directions to Hospitals Treating Non-alcoholic fatty liver disease

Risk calculators and risk factors for Non-alcoholic fatty liver disease surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]

Overview

Surgery is not the first-line treatment option for patients with non- Alcoholic fatty liver disease (NAFLD). However, gastric bypass surgery is recommended in patients with non-alcoholic fatty liver disease whose BMI is greater than 40 who psychologically stable and failed medical therapy.

Surgery

Indications

  • Patients with NAFLD and BMI greater than 40 who psychologically stable
  • In patients who failed medical therapy.

Surgical options

  • The size of the stomach is reduced either by stapling or banding, creating a small pouch, assisting with weight loss by inducing
  • The feasibility of liver transplantation depends on the stage of NAFLD at diagnosis.NAFLD is emerging as the second most common cause for liver transplant.[4][5]
    • Indication 1 End stage liver-disease 
    • Indication 2 Hepatocellular carcinoma (HCC) are the two most important indications for the liver transplant.
    • Outcome : After liver transplanation patients with or without NASH may survive 1,3 and 5 years and are increasinly at risk for cardio vascular risks.[6]

Complications

References

  1. Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J (2017). "Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies". J Clin Transl Hepatol. 5 (1): 67–75. doi:10.14218/JCTH.2016.00061. PMC 5411359. PMID 28507929.
  2. Boscolo M, Féry F, Cnop M (2017). "Beneficial Outcomes of Sleeve Gastrectomy in a Morbidly Obese Patient With Bardet-Biedl Syndrome". J Endocr Soc. 1 (4): 317–322. doi:10.1210/js.2017-00071. PMID 29264490.
  3. Colquitt JL, Pickett K, Loveman E, Frampton GK (2014). "Surgery for weight loss in adults". Cochrane Database Syst Rev (8): CD003641. doi:10.1002/14651858.CD003641.pub4. PMID 25105982.
  4. Germani G, Becchetti C (2017). "Liver transplantation for non-alcoholic fatty liver disease". Minerva Gastroenterol Dietol. doi:10.23736/S1121-421X.17.02467-9. PMID 29249127.
  5. Cholankeril G, Wong RJ, Hu M, Perumpail RB, Yoo ER, Puri P, Younossi ZM, Harrison SA, Ahmed A (2017). "Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes". Dig. Dis. Sci. 62 (10): 2915–2922. doi:10.1007/s10620-017-4684-x. PMID 28744836.
  6. Wang X, Li J, Riaz DR, Shi G, Liu C, Dai Y (2014). "Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis". Clin. Gastroenterol. Hepatol. 12 (3): 394–402.e1. doi:10.1016/j.cgh.2013.09.023. PMID 24076414.

Template:WS Template:WH